Personalized medicine can cut breast cancer risk

The time has come for breast cancer risk assessment, counseling and genetic testing to move from cancer specialists to the realm of primary care, according to a presentation at the AAAS annual meeting, held this year in Boston. more  

Moving beyond tamoxifen: Drug discovery and the future of selective hormone receptor modulators

How did a failed contraceptive become the first targeted therapy for the treatment of breast cancer" The transformation of tamoxifen, from cast-off to lifesaver, laid the foundation for a new class of therapeutics – selective estrogen receptor modulators – that could treat or prevent a variety of human diseases. more

Blacks awaiting lung transplants more likely to die or be denied than whites

Blacks with chronic obstructive pulmonary disease (COPD) were less likely to receive a lung transplant and more likely to die or be removed from the transplant list than whites, according to Columbia University Medical Center researchers. more  

Tumor-targeting viral therapy slows neuroblastoma, malignant peripheral nerve sheath tumors

Researchers in a multi-institutional study led by Cincinnati Children’s Hospital Medical Center slowed the growth of two particularly stubborn solid tumor cancers – neuroblastoma and peripheral nerve sheath tumors –without harming healthy tissues by inserting instructions to inhibit tissue growth into an engineered virus, according to study results published in the February 15 Cancer Research. more

New findings on emerging contaminants  

American and Canadian scientists are finding that out of sight, out of mind can no longer be the approach we take to the chemicals in our waters. Substances that we use everyday are turning up in our lakes, rivers and ocean, where they can impact aquatic life and possibly ourselves. more

Blood pressure drug may have added benefit 

University of Kentucky researchers have discovered a possible added benefit of a novel new drug that lowers blood pressure. more

PSA testing can predict advanced prostate cancer

A single prostate specific antigen (PSA) test taken before the age of 50 can be used to predict advanced prostate cancer in men up to 25 years in advance of a diagnosis, according to a new study published by researchers at Memorial Sloan-Kettering Cancer Center in New York and Lund University in Sweden. The findings, published in the online open- access journal BMC Medicine, should help physicians be able to identify men who would benefit from intensive prostate cancer screenings over their lifetime. more

© RAmEx Ars Medica,Inc. All rights reserved.

Information appearing on the Vidyya Medical News Service is not intended as a substitute for professional medical care. Seek professional medical help and follow your health care provider's advice.

Interested in subscribing to our daily e-mail newsletter? Send an email to Vidyya@Ramex.com with the word subscribe in the subject field.